CHMP gives Pradaxa new contraindication, limits long-term use of calcitonin medicines
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has added Sanofi's antiarrythmic drug Multaq (dronedarone) to the list of contraindicated medicines associated with Boehringer Ingelheim’s anti-coagulant Pradaxa (dabigatran etexilate). Systemic ketoconazole, cyclosporine, itraconazole and tacrolimus are also contraindicated.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.